Register
Login:
Share:
Email Facebook Twitter




Quick Poll
QUICK POLL >
Do you invest in funds?




FUM Share Chat - RSS Feed

Futura Medical Share Chat (FUM)



Share Price: 29.75Bid: 29.00Ask: 30.50Change: 0.00 (0.00%)No Movement on Futura Med.
Spread: 1.50Spread as %: 5.17%Open: 29.75High: 29.75Low: 29.75Yesterday’s Close: 29.75


Share Discussion for Futura Med. (FUM)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


Premium Membership
AwkwardTurtle
Posts: 14,443
Premium Chat Member
Observation
Opinion:No Opinion
Price:61.00
Fum
14 Sep '12
Damn it...well done all
 
Babbler2
Posts: 17,714
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:61.00
Patience
14 Sep '12
Must learn patience... never!
BH26
Posts: 1,195
Observation
Opinion:No Opinion
Price:58.00
The ceo's delighted...
14 Sep '12
14 September 2012
Placing to raise £2.08 million
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce a Placing by Nomura Code Securities Limited in which gross proceeds of £2.08 million are being raised through the issue of 3,654,969 new ordinary shares of 0.2 pence each in Futura ("New Ordinary Shares") to existing institutional investors at a price of 57 pence per share. The Placing represents approximately 5% of the Company's issued share capital.
The £2.0 million net proceeds of the Placing, which is underwritten by Nomura Code Securities Limited, will be used to provide additional working capital. The Placing strengthens the balance sheet and will assist the Company in its out-licensing negotiations as well as the ongoing development of its product pipeline.
The New Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Application has been made to the London Stock Exchange and it is anticipated that trading of the New Ordinary Shares will commence on AIM at 8:00am on 19 September 2012.
Futura's total issued share capital following the admission of the New Ordinary Shares will be 77,369,081. The total number of voting rights in the Company will be 77,369,081.
James Barder, Futura's Chief Executive, said: "We're delighted to have completed this oversubscribed fundraising and by the support that we have received from our existing institutional shareholders."
Babbler2
Posts: 17,714
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:58.00
Placing
14 Sep '12
Placing @ 57p - well done those who got in @ 40p. :/
mulledwine
Posts: 35,667
Off Topic
Opinion:No Opinion
Price:50.50
FUM
11 Sep '12
Finance

Cash and cash equivalents at 30 June 2012 was £1.86 million (31 December 2011: £2.58 million) with a net cash outflow of £723k in the period. We continue to manage our financial resources carefully.

In the period under review, we earned milestone payments totalling £75k (year ended 31 December 2011: £158k). The retained loss for the six months ended 30 June 2012 was £959k. Research and development ("R&D") costs of £683k were higher than that for the corresponding six month period ended 30 June 2011: £515k (year ended 31 December 2011: £1,481k) as we are investigating new products to add to the development pipeline. Other administrative costs of £481k were higher than that for the corresponding six month period ended 30 June 2011: £319k (year ended 31 December 2011: £776k) and includes the full year charge for 2012 of the revision to the policy on Non-Executive Directors' remuneration.

Outlook

We continue to make good progress across our portfolio but our primary focus in the short term is on the commercialisation of CSD500 now that we have regained control of the product. We have a clear commercialisation strategy for CSD500 and remain confident of licensing the product to one or more commercial partners.
mulledwine
Posts: 35,667
Off Topic
Opinion:No Opinion
Price:50.50
FUM
11 Sep '12
James Barder, Futura's Chief Executive, said: "We continue to make good progress across our portfolio but our primary focus in the short term is on the commercialisation of CSD500 now that we have regained control of the product. We have a clear commercialisation strategy for CSD500 and remain confident of licensing the product to one or more commercial partners."
mulledwine
Posts: 35,667
Off Topic
Opinion:No Opinion
Price:50.50
FUM
11 Sep '12
Interim Results for the six months ended 30 June 2012

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce interim results for the six months ended 30 June 2012.

Key Events

· CSD500 and MED2002 - Rights regained for both products

· PET500 - Upcoming US launch by Ansell under the LifeStyles® brand

· CRF100 - Cellulite reduction product clinical trial completed

· John Clarke joined the Company as Non-Executive Chairman to lead the next stages
in the Company's development

· Net loss of £0.96 million in the period with net cash outflow of £0.72 million

· Cash resources of £1.86 million at 30 June 2012
mulledwine
Posts: 35,667
Off Topic
Opinion:No Opinion
Price:50.50
FUM
11 Sep '12
Babbler2
Posts: 17,714
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:51.50
yeah
7 Sep '12
Hindsigt - wonderful thing. 40p was obviously bounce point. Where will it stop this time? GL all still in. Notch it up to another mistake made...





Sign up for Live Prices


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.